According to CoinMeta, Hengrui Medicine announced that its subsidiaries, Suzhou Shengdia Biopharmaceutical Co., Ltd. and Shanghai Shengdia Pharmaceutical Co., Ltd., have recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration regarding SHR-A2009 for injection and Adelali monoclonal antibody injection. The approval allows for Phase II clinical trials to be conducted in patients with non-small cell lung cancer using SHR-A2009 in combination with Adelali monoclonal antibody, or in combination with third-generation EGFR TKI. These clinical trials are set to begin shortly. The cumulative R&D investment for the SHR-A2009 related project is approximately 329 million yuan (unaudited), while the cumulative R&D investment for the Adelali monoclonal antibody injection related project is about 1.252 billion yuan (unaudited).